Robert W. Baird Reaffirms Outperform Rating for Apellis Pharmaceuticals (NASDAQ:APLS)

Robert W. Baird reiterated their outperform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $100.00 price objective on the stock.

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company lowered their target price on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an equal weight rating for the company in a report on Thursday, May 23rd. Mizuho reduced their target price on shares of Apellis Pharmaceuticals from $60.00 to $52.00 and set a neutral rating on the stock in a research report on Monday, April 29th. Citigroup cut their price target on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a buy rating on the stock in a report on Wednesday, May 8th. HC Wainwright reaffirmed a buy rating and issued a $92.00 price target on shares of Apellis Pharmaceuticals in a report on Tuesday, May 28th. Finally, Wedbush cut their price target on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a neutral rating on the stock in a report on Wednesday, April 17th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of Moderate Buy and an average price target of $74.75.

Apellis Pharmaceuticals Stock Up 4.0 %

Shares of NASDAQ:APLS opened at $38.88 on Tuesday. The company has a quick ratio of 3.02, a current ratio of 3.77 and a debt-to-equity ratio of 0.35. Apellis Pharmaceuticals has a fifty-two week low of $19.83 and a fifty-two week high of $73.80. The firm’s 50-day simple moving average is $39.67 and its 200-day simple moving average is $52.13. The company has a market cap of $4.72 billion, a price-to-earnings ratio of -11.24 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The firm had revenue of $172.33 million during the quarter, compared to analysts’ expectations of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. The business’s revenue for the quarter was up 284.3% compared to the same quarter last year. During the same quarter last year, the business earned ($1.56) earnings per share. As a group, equities research analysts predict that Apellis Pharmaceuticals will post -1.07 earnings per share for the current year.

Insider Transactions at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the completion of the transaction, the director now owns 136,998 shares in the company, valued at $5,375,801.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the completion of the transaction, the director now owns 136,998 shares in the company, valued at approximately $5,375,801.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pascal Deschatelets sold 78,907 shares of the stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $42.35, for a total transaction of $3,341,711.45. Following the completion of the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $47,261,880.05. The disclosure for this sale can be found here. Insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Future Financial Wealth Managment LLC purchased a new stake in Apellis Pharmaceuticals during the first quarter valued at about $29,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Apellis Pharmaceuticals during the first quarter valued at about $89,000. CWM LLC lifted its stake in Apellis Pharmaceuticals by 299.9% during the second quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after buying an additional 3,113 shares in the last quarter. CWA Asset Management Group LLC purchased a new stake in Apellis Pharmaceuticals during the fourth quarter valued at about $205,000. Finally, HC Advisors LLC purchased a new stake in Apellis Pharmaceuticals during the fourth quarter valued at about $210,000. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).